<!DOCTYPE html>
<html lang="en">

<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, shrink-to-fit=no">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <title>Intravitreal Aflibercept 8 mg - Overview</title>
  <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/css/bootstrap.min.css" rel="stylesheet">
  <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/js/bootstrap.bundle.min.js"></script>
  <link rel="stylesheet" href="assets/css/styles.css">
  <link rel="stylesheet" href="assets/fonts/fontawesome-all.min.css">
  <script src="https://ajax.googleapis.com/ajax/libs/jquery/3.7.0/jquery.min.js"></script>
  <script src="assets/js/javascript.js"></script>
</head>



<body>
  <div class="row">
    <h3 style="font-size: 28px; width: 100%; color: white; font-weight: bold; background: #00617f; padding-top: 10px; padding-bottom: 10px;padding-left: 25px;">Intravitreal Aflibercept 8 mg - Overview</h3>
  </div>


  <div class="container-fluid">
    <div id="first">
      <h1>
        Summary
      </h1>
      <ul class="bullet">
        <li>
          At this current time, any dosage other than IVT-AFL 2 mg is not an approved dosage for Eylea. Bayer does not recommend the use of its products in any manner inconsistent with approved product labeling.
        </li>
        <li>
          Bayer and Regeneron are jointly investigating the safety and efficacy of IVT-AFL 8 mg in patients with nAMD and DME.
        </li>
        <li>
          <b>PULSAR</b> is an ongoing, randomized, double-masked, Phase 3, 96-week study to evaluate the efficacy and safety profile of an IVT-AFL 8 mg vs 2 mg for the treatment of nAMD.<sup>1</sup>
        </li>
        <li>
           <b>PHOTON</b> is an ongoing, randomized, double-masked, Phase 2/3, 96-week study to evaluate the efficacy and safety profile of IVT-AFL 8 mg vs 2 mg for the treatment of DME.<sup>2</sup>
        </li>
        <li>
          <b>CANDELA</b> was a randomized, multicenter, single-masked, Phase 2 study that evaluated the efficacy and safety profile of IVT-AFL 8 mg vs 2 mg in treatment na√Øve patients with nAMD.<sup>3</sup>
        </li>
      </ul>
    </div>
    </div>

    <div class="btn-toolbar" role="group">
      <a href="PULSAR.html" target="_blank" class="btn btn-trial mr-1">PULSAR</button></a>
      <a href="PHOTON.html" target="_blank" class="btn btn-trial mr-1">PHOTON</button></a>
      <a href="CANDELA.html" target="_blank" class="btn btn-trial mr-1">CANDELA</button></a>
    </div>

    <p style="font-size: 28px; font-weight: bold; margin-bottom: 20px; display: flex; justify-content: center; text-align: center; color: green;">
      For more information please select a clinical trial above
    </p>

  
  <footer class="fixed-bottom">
    <div class="container-fluid">
      <button type="button" class="btn btn-abbrev" data-bs-toggle="popover" data-bs-container="body" data-bs-html="true" onclick="changeIcon(this)" title="Abbreviations" data-bs-content="
        <strong>2q8</strong> 2 mg every 8 weeks<br>
        <strong>8q12</strong> 8 mg every 12 weeks<br>
        <strong>8q16</strong> 8 mg every 16 weeks<br>
        <strong>AE</strong> adverse events<br>
        <strong>BCVA</strong> best-corrected visual acuity<br>
        <strong>CNV</strong> choroidal neovascularization<br>
        <strong>CRT</strong> central retinal thickness<br>
        <strong>DRM</strong> dose regimen modification<br>
        <strong>ETDRS</strong> Early Treatment Diabetic Retinopathy Study<br>
        <strong>FAS</strong> full analysis set<br>
        <strong>IOP</strong> intraocular pressure<br>
        <strong>IRF</strong> intraretinal fluid<br>
        <strong>IVT-AFL</strong> intravitreal aflibercept<br>
        <strong>nAMD</strong> neovascular age-related macular degeneration<br>
        <strong>pts</strong> patients<br>
        <strong>SAF</strong> safety analysis set<br>
        <strong>SRF</strong> subretinal fluid<br>">
      <i id ="fa" class="fas fa-list"></i>
      </button>

     <button type="button" class="btn btn-ref" data-bs-toggle="popover" data-bs-container="body" data-bs-html="true" title="References" onclick="changeIcon(this)" data-bs-content="
      <ol>
        <li>
         Korobelnik JF. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 48-week results from the Phase 3 PULSAR Trial. Presented at: 55th Annual Scientific Meeting of The Retina Society; November 2-5 2022; Pasadena, CA. 
         <br><a href='https://investor.regeneron.com/static-files/d2cb2519-182f-42a6-8ac4-04544883febc' target='_blank'>Link</a>
       </li>
       <li>
        Brown DM. Intravitreal Aflibercept Injection 8 mg for DME:
        48-Week Results From the Phase 2/3 PHOTON Trial. Presented at: 55th Annual Scientific Meeting of The Retina Society; November 2-5 2022; Pasadena, CA. 
        <br><a href='https://investor.regeneron.com/static-files/c0c47d3b-926b-44f9-8d9a-5a3a3fd3bdd0' target='_blank'>Link</a>
      </li>
       <li>
        Brown, DM. CANDELA: High dose aflibercept for neovascular AMD, in Angiogenesis, Exudation, and Degeneration 2022. 2022. Bascom Palmer Eye Institute: Virtual.
      </li>
      </ol>">
    <i id="fa" class="fas fa-scroll"></i>
    </button>
    </div>
    <a href="#" id="scroll" style="display: none;"><span></span></a>
  </footer>   

  </div>
</div>

<script>  
  var popoverTriggerList = [].slice.call(document.querySelectorAll('[data-bs-toggle="popover"]'))
  var popoverList = popoverTriggerList.map(function (popoverTriggerEl) 
  {
    return new bootstrap.Popover(popoverTriggerEl)
  });
</script>
</body>

</html>